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Mutations in LRRK2 Cause Autosomal-Dominant
Parkinsonism with Pleomorphic Pathology
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tion) in a gene encoding a large, multifunctional pro-
Alexander Zimprich,1,2,11 Saskia Biskup,3,11
Petra Leitner,1 Peter Lichtner,3 Matthew Farrer,4
Sarah Lincoln,4 Jennifer Kachergus,4 Mary Hulihan,4
Ryan J. Uitti,5 Donald B. Calne,6 A. Jon Stoessl,6 tein, LRRK2 (leucine-rich repeat kinase 2). It belongs
to the ROCO protein family and includes a proteinRonald F. Pfeiffer,7 Nadja Patenge,1
Iria Carballo Carbajal,1 Peter Vieregge,8 kinase domain of the MAPKKK class and several other
major functional domains. Within affected carriers ofFriedrich Asmus,1 Bertram Mu¨ller-Myhsok,9
Dennis W. Dickson,4 Thomas Meitinger,3,10,* families A and D, six post mortem diagnoses reveal
brainstem dopaminergic degeneration accompaniedTim M. Strom,3,10 Zbigniew K. Wszolek,5,*
and Thomas Gasser1,* by strikingly diverse pathologies. These include abnor-
malities consistent with Lewy body Parkinson’s dis-1Department of Neurodegenerative Disease
Hertie Institute for Clinical Brain Research ease, diffuse Lewy body disease, nigral degeneration
without distinctive histopathology, and progressiveUniversity of Tu¨bingen
72076 Tu¨bingen supranuclear palsy-like pathology. Clinical diagnoses
of Parkinsonism with dementia or amyotrophy or both,Germany
2 Neurological Department with their associated pathologies, are also noted.
Hence, LRRK2 may be central to the pathogenesis ofMedical University of Vienna
1090 Vienna several major neurodegenerative disorders associ-
ated with parkinsonism.Austria
3 Institute of Human Genetics
GSF National Research Center Introduction
for Environment and Health
85764 Neuherberg Parkinson’s disease (PD) is a common neurodegenera-
Germany tive disorder characterized by a progressive loss of do-
4 Department of Neuroscience paminergic neurons of the substantia nigra, associated
5 Department of Neurology with the formation of fibrillar aggregates composed of
Mayo Clinic -synuclein and other proteins (Lewy bodies and Lewy
Jacksonville, Florida 32224 neurites). In most cases, PD occurs as a sporadic dis-
6 Pacific Parkinson’s Research Centre ease of unknown etiology, but in rare instances, point
University of British Columbia mutations (Polymeropoulos et al., 1997) or multiplica-
Vancouver, British Columbia V6T 2B5 tions (Singleton et al., 2003; Chartier-Harlin et al., 2004)
Canada of the -synuclein gene can cause autosomal-dominant
7 Department of Neurology parkinsonism, which resembles sporadic disease in
University of Tennessee Health Science Center many aspects. Recessive forms of parkinsonism have
Memphis, Tennessee 38103 been recognized that are caused by mutations in the
8 Department of Neurology genes for parkin (Kitada et al., 1998), DJ-1 (Bonifati et
Klinikum Lemgo al., 2003), and PINK1 (Valente et al., 2004). Additional
32657 Lemgo loci have been mapped on chromosomes 2p (Gasser et
Germany al., 1998), 12cen (Funayama et al., 2002), 1q (Hicks et
9 Computational Genetics Group al., 2002), and 2q (Pankratz et al., 2003).
Max Planck Institute for Psychiatry As -synuclein aggregation is a pathologic feature
80804 Munich common to sporadic and dominantly inherited forms
Germany of PD, as well as other neurodegenerative diseases,
10Institute of Human Genetics including dementia with Lewy bodies (DLB) and multiple
Technical University Munich system atrophy (MSA), those diseases have been collec-
81675 Munich tively called “-synucleinopathies” (reviewed by Farrer
Germany et al., 1999). Other forms of parkinsonism are associated
with the accumulation of filaments within neurons and
glia, which are composed of the microtubule-associated
protein tau. Mutations in this gene (MAPT) explain atSummary
least a subgroup of families with frontotemporal demen-
tia with parkinsonism linked to chromosome 17 (FTDP-We have previously linked families with autosomal-
dominant, late-onset parkinsonism to chromosome 17; Hutton et al., 1998), while sporadic cases with tau
pathology most commonly present as progressive su-12p11.2-q13.1 (PARK8). By high-resolution recombi-
nation mapping and candidate gene sequencing in 46 pranuclear palsy (PSP) or corticobasal degeneration
(CBD) (Dickson, 1999). Based on the putative central
role of the tau protein in these diseases, they have been*Correspondence: meitinger@gsf.de (T.M.); wszolek.zbigniew@
called “tauopathies” (reviewed in Arvanitakis and Wszo-mayo.edu (Z.K.W.); thomas.gasser@med.uni-tuebingen.de (T.G.)
11These authors contributed equally to this work. lek, 2001; Ghetti et al., 2003).
Neuron
602
Figure 1. Pedigree Structure of the Two Largest Kindreds with LRRK2 Mutations
Shown are family A (German-Canadian) and family D (Western Nebraska). Blackened symbols denote affected family members. An asterisk
denotes a genotyped individual, with “m” for mutation carriers and “wt” for wild-type LRRK2. To maintain confidentiality, genotypes of some
unaffected individuals in families A and D are not shown. Additionally, the structure of the pedigrees has been altered, and the genders of
individuals in some of the youngest generations have been disguised.
Recently, we have shown that two large families with using the mutation as a marker gives maximum LOD
scores of 3.78 at   0 and provides the statisticalautosomal-dominant late-onset parkinsonism (families
A and D) are linked to the PARK8 locus on chromosome burden of proof for pathogenicity.
In the second family that was previously linked to12p11.2-q13.1 (OMIM# 607060) (Zimprich et al., 2004),
originally mapped in a Japanese family by Funayama the PARK8 locus, family D (Wszolek et al., 2004), 34
individuals were genotyped (10 affecteds and 24 unaf-et al. (2002). High-resolution recombination mapping,
candidate gene sequencing, and the identification of fecteds). All affecteds were heterozygous for the
4321CT (R1441C) mutation. Of the 24 clinically unaf-pathogenic mutations within linked families is reported
in this article. fected individuals who were genotyped, only two were
older than 60 years of age and were mutation carriers.
These individuals are considered to be at risk and likelyResults
presymptomatic, given that the average age of onset in
this family is 65 years (Wszolek et al., 2004). To protectWithin our linked families, haplotype analysis of obligate
recombinants initially refined a candidate region of 13 the confidentiality of family members, some pedigree
symbols and genotypes have been omitted and genderMb, between flanking markers D12S1692 and D12S85.
We subsequently sequenced a total of 29 genes in the has been disguised in the pedigrees (Figure 1).
To estimate the prevalence of LRRK2 mutationsregion, in two patients from each family. Supplemental
Table S1 (http://www.neuron.org/cgi/content/full/44/4/ among PD families, one index patient each from 44 addi-
tional families with PD (32 with features consistent with601/DC1/) lists the 29 genes in order of their genomic
position. The primer pairs, sequence variants identified, autosomal-dominant PD and 12 affected sib-pairs) were
subsequently sequenced. We identified two further mis-and sequence chromatograms obtained are available
upon request. Missense mutations were identified in a sense and one putative splice site mutation, all in fami-
lies with typical late-onset PD, compatible with a domi-large gene, LRRK2 (leucine-rich repeat kinase 2), in fam-
ily A (Y1699C; 5096AG) and in family D (R1441C; nant transmission: (I1122V; 3364AG) in family 21,
(I2020T; 6059TC) in family 32, and (L1114L; 3342AG)4321CT). Both mutations segregated with disease in
these two families (Figure 1) and were not found in more in family 38, which is 6 bp away from the exon/intron
border. Affected individuals in an additional family (469)than 1000 control individuals or 300 sporadic PD pa-
tients. were found to carry the same mutation as family D
(R1441C; 4321CT). These two families are not knownIn family A (Wszolek et al., 1997), 16 individuals were
genotyped (8 unaffecteds and 8 affecteds). All affecteds to be related, nor do they share haplotypes for the clos-
est flanking microsatellite repeat markers D12S2194,were heterozygous for the mutation, and all unaffecteds
aged over 60 were wild-type. Individuals IV:1 and IV:2 D12S1048, or three newly developed intragenic repeat
markers within introns (see Experimental Procedures).(family A) were not included in our initial linkage analysis
(Zimprich et al., 2004); both individuals have now been This suggests the mutations are either extremely ancient
or arose independently. Pedigree structures and clinicalgenotyped. Recalculation of the two-point LOD scores
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LRRK2 is indeed expressed in brain and to establish
the complete cDNA sequence, we amplified the whole
gene from human brain cDNA (Cat# 7400-1, Clontech,
BD Bioscience, San Jose, CA) using overlapping primers
predicted by homology searches (see Supplemental
Data). The resulting gene spans a genomic region of
144 Kb, with 51 exons encoding 2527 amino acids (Fig-
ure 3B). The expression pattern of LRRK2 was subse-
quently examined in several tissues. We hybridized hu-
man brain and multiple tissue Northern blots with a 1078
bp 3 cDNA probe and found expression in most brain
regions, albeit at very low levels. There appeared to be
a major transcript of 9 kb and a minor transcript of 8
kb, which may be explained by the alternative use of
polyadenylation [poly(A)] sites. This would be in concor-
dance with two mRNAs, deposited under the accession
numbers AL832453 and AL834529, which make use ofFigure 2. Pedigree Structures of Smaller Families with LRRK2 Muta-
tions canonical poly(A) sites (aataaa) at positions 7962 and
Blackened symbols denote affected family members. An asterisk 8944, respectively. Multiple, very weak bands at lower
denotes a genotyped individual, with “m” for mutation carriers and sizes were found that suggested alternative splicing
“wt” for wild-type LRRK2. To protect confidentiality, the genotypes (data not shown).
of some unaffected individuals of family 469 are not shown. Addi-
Using real-time RT-PCR and RNA isolated from adulttionally, the structure of the pedigrees has been altered, and the
and fetal whole brain and from different brain regions, wegender of individuals in the youngest generations has been dis-
assessed quantitative gene expression and alternativeguised.
splicing. We designed primers to generate specific PCR
products for exons 1–3, exons 12–13, and exons 32–34,
and pathological details of affected patients within these respectively. Within the same tissue or brain region,
smaller families are illustrated in Figure 2. Clinical and transcript levels of all three assays showed no signifi-
genetic information for all families with LRRK2 mutations cant differences. We found low, but consistent, expres-
is summarized in Table 1. While smaller families may sion of full-length LRRK2 in most brain regions, slightly
not demonstrate significant evidence for linkage, the higher in putamen, substantia nigra, and lung (Figure 4).
mutations appear to segregate with the disease in all Whether any of these transcripts result in translated,
of these families and none were found in controls. Three functional protein awaits the generation of specific anti-
of the amino acid substitutions (R1441C, Y1699C, and bodies. Of note, in adult human brain tissue, exon 6 was
I1122T) are highly conserved across species (Figure 3C). constitutively expressed within the full-length mRNA.
LRRK2 was covered by several partial cDNA clones LRRK2 (also referred to as dardarin [see Paisa´n-Ruı´z
deposited in public data banks. From cross-species se- et al., 2004, published online October 22 and appearing
quence alignments, it became clear that the clones were in this issue of Neuron]) can be considered a member
of the recently defined ROCO protein family (Bosgraafincomplete toward the 5 end. To confirm whether
Table 1. Clinical and Pathologic Features of Kindreds with LRRK2 Mutations
Family A D 21 32 38 469
Mutation Y1699C R1441C I1122V I2020T 3342AG R1441C
Mean age at onset 53 (35–65) 65 (48–78) 51 (49–53) 54 (48–59) 73 (68–77) 56 (52–60)
Mean disease duration 13 (5–18) 13 (4–26) 18 (17,19) 20 (12–27) 11 (7,14) 23 (21–26)
Initial Signs RT B, RT B B RT RT
Bradykinesia      
Rigidity      
Resting tremor      
Postural instability     - 
Response to levodopa      
Long-term complications   - - - -
Other features Two cases had amyotrophy - - - - -
and two cases had dementia
Pathologic features Two cases had “nonspecific” All cases had SN neuronal loss. NA NA NA NA
SN degeneration with ubiqui- One case had “nonspecific”
tin-positive neuronal inclu- SN degeneration with ubiqui-
sions. One had concurrent AD tin-positive neuronal inclu-
and one had mild motor neu- sions. Two cases had Lewy
ron disease. bodies—one brainstem-type
and one diffuse-type. One
case had PSP-like changes.




Figure 3. Structure of LRRK2
(A) Axon positions.
(B) Schematic drawing of LRRK2, with do-
mains, primer positions for cDNA amplifica-
tion, and positions of mutations.
(C) Protein alignment of three mutations con-
served among the following: hs, Homo sapi-
ens; mm, Mus musculus; rn, Rattus norvegi-
cus; ce, Caenorhabditis elegans; and dm,
Drosophila melanogaster.
and Van Haastert, 2003), as predicted in silico by the serine/threonine and tyrosine protein kinases. They ex-
ert their function by catalyzing the transfer of thepresence of two conserved domains: (1) a Roc (Ras
in complex proteins) domain that belongs to the Ras/ -phosphate of ATP to tyrosine residues on protein sub-
strates (Hubbard and Till, 2000). Finally, WD40 domainsGTPase superfamily; and (2) a COR domain (C-terminal
of Roc) that is also characteristic for this protein family. have been previously implicated in signal transduction,
pre-mRNA processing, and cytoskeleton assembly (SmithRas/GTPase domains are involved in the reorganization
of the actin cytoskeleton in response to external stimuli. et al., 1999).
The sequence of this newly identified gene, therefore,They also have roles in cell transformation by Ras, as
well as in cytokinesis, focal adhesion formation, and suggests multiple functions. As we have found muta-
tions in different functional domains, it is unclear whichthe stimulation of stress-activated kinase (Ridley, 2001).
Three further conserved domains can be identified: (1) domain or domains are related to neurodegeneration. It
is likely, however, that LRRK2 may be central to a rangea leucine-rich repeat (LRR), consisting of 12 strands of
a 22–28 amino acid motif, present in a tandem array; (2) of neurodegenerative processes based upon available
evidence. First, LRRK2 mutations appear to be a com-a tyrosine kinase catalytic domain (TyrKc); and (3) a
WD40 domain. Although proteins containing LRRs are mon cause of autosomal-dominant parkinsonism. In the
present study, we identified six independent mutationsassociated with diverse functions, such as hormone re-
ceptor interactions, enzyme inhibition, cell adhesion, in 34 families with autosomal-dominant PD. Second,
affected individuals with LRRK2 mutations exhibit strik-cellular trafficking, splicing, and substrate binding for
ubiquitination, a common property involves protein-pro- ingly variable pathologic changes (Wszolek et al., 2004),
representing aspects of several of the major neurode-tein interaction (Kobe and Kajava, 2001). Enzymes with
TyrKc domains belong to an extensive family of proteins generative diseases (Figure 5).
The common feature of the neuropathology of six af-that share a conserved catalytic core common to both
Figure 4. Transcript Levels of LRRK2 in Dif-
ferent Human Tissues
Quantitative RT-PCR assays show no differ-
ential expression of three regions of the
LRRK2 transcripts within the same tissue.
Transcript levels are given as ratios of
LRRK2/h-PBGD, a low-copy housekeeping
gene, normalized to adult whole brain expres-
sion as 100%. Note the comparably high ex-
pression levels of LRRK2 transcripts in puta-
men and substantia nigra, brain regions
vulnerable to neurodegeneration in PD.
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ease. In the final individual, there were tau-immunoreac-
tive neuronal and glial lesions that morphologically re-
sembled lesions of PSP; however, the density and
distribution of the lesions was not diagnostic of PSP.
Alzheimer type pathology, which might be expected
given the advanced age at autopsy, was detected in
several individuals, and one met neuropathologic crite-
ria for Alzheimer’s disease. Several individuals in family
A had clinical features of motor neuron disease, and
there was mild decrease of anterior horn cells, gliosis,
and axonal spheroids in these cases (Wszolek et al.,
1997).
Discussion
Although only a small proportion of PD cases are caused
by gene mutations with high penetrance, identification
of these genes has had a major impact on the under-
standing of the molecular mechanisms leading to dopa-
minergic neurodegeneration. Those mechanisms in-
clude the aggregation of proteins such as -synuclein
and tau, deficits in ubiquitin-proteasome protein degra-
dation, or mitochondrial dysfunction and oxidative
stress. Until now, it was assumed that these represented
separate molecular pathways, all eventually leading to
neuronal death, but originating from different initial in-
sults. This view will need to be revised given the pres-
ent findings.
LRRK2 appears to be central to the etiology of not just
one but several neurodegenerative diseases, including
those associated with -synuclein and tau pathologyFigure 5. Substantia Nigra Pathology in Families A and D
and clinical parkinsonism. Previously, it was shown thatSummary of substantia nigra pathology in six autopsies from family
-synuclein and tau pathologies may be closely linked.A (III:29, [A]–[D]; II:27, [E] and [F]) and family D (III:20, [G]–[J]; III:14,
For example, tau-aggregations have been found in the[K] and [L]; III:21, [M]–[O]; and IV:20, [P]–[R]). Three cases had non-
specific neuronal loss and gliosis in the substantia nigra (hematoxy- brains of patients carrying pathogenic A53T mutation in
lin and eosin stain) (A and P) with ubiquitin-immunoreactive neuronal the gene for -synuclein (Duda et al., 2002). Tau has
lesions. Ubiquitin immunohistochemistry revealed a range of le- also been shown to colocalize with a subset of Lewy
sions, including irregular cytoplasmic inclusions (arrow in B) (B and bodies in sporadic PD (Ishizawa et al., 2003). Moreover,
D), curvilinear dystrophic neurites (C and E), granular and foamy
tau and -synuclein have been shown to reciprocallyaxonal spheroids (R), and multiple nuclear inclusions (arrows in D
promote fibril formation in vitro (Giasson et al., 2003).and Q) (D, F, and Q).-synuclein immunohistochemistry was positive
The major pathogenic protein aggregating in AD, A,in two individuals, showing many cortical Lewy bodies (G) and corti-
cal Lewy neurites (H) in one case, as well as typical brainstem-type has been shown to promote fibrillization of tau and en-
Lewy bodies (arrow in I, K, and L) or pleomorphic Lewy bodies (J) hanced formation of neurofibrillary tangles in transgenic
in the substantia nigra and brainstem nuclei. One case had tau- animal models (Gotz et al., 2001; Lewis et al., 2001).
immunoreactive lesions similar to those seen in PSP, including glo- Interestingly, a genomic region overlapping the PARK8
bose neurofibrillary tangles (M and N), tufted astrocytes (arrow in
locus has been identified in a linkage study of familialM), and oligodendroglial coiled bodies (M and O).
Alzheimer disease (Scott et al., 2000). Evidence for link-
age was derived in a large part from families with at
fected individuals from families A and D who have come least one member with autopsy-proven diffuse Lewy
to autopsy is neuronal loss and gliosis in the substantia body disease. Whether this linkage result reflects vari-
nigra, which is the likely pathologic substrate of parkin- ants in the LRRK2 gene remains to be determined.
sonism. In three of the individuals (two from family A We hypothesize that the function(s) of LRRK2 are cru-
and one from family D), there was nonspecific loss of cial to the initiation and development of several neurode-
dopaminergic neurons, with ubiquitin-immunoreactive generative disorders. Potentially, LRRK2 may be re-
cytoplasmic and nuclear inclusions. The latter were simi- sponsible for the phosphorylation of both -synuclein
lar to Marinesco bodies, while the neuronal cytoplasmic and tau; its kinase activity could be a key event in the
inclusions appear to be novel and await further charac- accumulation and aggregation of these unfolded pro-
terization. Two individuals (both from family D) had Lewy teins within degenerating neurons.
body pathology. In one individual, who died prematurely
Experimental Proceduresfollowing a neurosurgical ablation procedure, Lewy bod-
ies were relatively restricted to brainstem nuclei as in
Genetic Analyses
typical PD. In the other individual, there was widespread DNA Extraction
-synuclein pathology, including Lewy bodies and Lewy Genomic DNA from peripheral blood lymphocytes was extracted
using standard protocols. Blood was collected after obtaining in-neurites, in a pattern typical of diffuse Lewy body dis-
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formed consent from all participating family members. All human quantified using the h-PBGD Housekeeping Gene Set (Roche-
Applied Science). Relative transcript levels were calculated as ratiosstudies are approved by institutional review boards of participat-
ing institutions. of LRRK2/PBGD normalized to adult whole brain adult expression
as 100%.Sequence Analysis
Genomic sequences and annotations were obtained from the Na-
tional Center for Biotechnology Information (NCBI) (http://www. Acknowledgments
ncbi.nlm.nih.gov/) and University of California, Santa Cruz (UCSC)
(http://genome.ucsc.edu/). Primers for mutation screening were de- The three corresponding authors are equally responsible senior au-
signed using Primer3 software integrated into script to allow for thors. Drs. Gasser and Meitinger led the genetic investigations, and
automated primer design (http://ihg.gsf.de/ihg/ExonPrimer.html). We Dr. Wszolek was responsible for the longitudinal clinical study of
amplified exon sequences and exon-intron boundaries with intronic the large families. We gratefully acknowledge the participation of
primers and sequenced them directly by BigDye Terminator Cycle all patients and family members. The work was funded in part by
sequencing kit (Applied Biosystems). Primer sequences are pro- the German National Genome Network (NGFN; Grant number
vided in the Supplemental Data. 01GS0116, German Ministry for Education and Research), the Com-
Between markers D12S1692 and D12S85, a total of 29 genes or petence Network Parkinson’s disease (German Ministry for Educa-
RNAs were sequenced. These sequences are listed in Supplemental tion and Research, Grant number 01Gl0201), the National Institutes
Table S1. In the gene PPHLN1 (Periphilin), we detected an amino of Health, the National Institute of Neurologic Disorders and Stroke,
acid change (K142E) in one small family of two affecteds. We cannot the Morris K. Udall Parkinson’s Disease Research Center of Excel-
determine whether this alteration is, in fact, pathogenic, because no lence (grant awarded to the Mayo Clinic Jacksonville, P50-NS40256-
further nucleotide change was found, even after extensive mutation 06), the Canadian Institutes for Health Research, and the Pacific
analysis in all of the other families investigated. Parkinson’s Research Institute. Dr. Y. Tsuboi, Mrs. E. Wszolek, S.
Haplotype Analysis Calne, B. Pfeiffer, A. Strongosky, and J. Searcy helped to collect
Haplotypes were constructed by hand using the repeat markers clinical material. Drs. P. McGeer, K. Berry, and R. McComb provided
previously used for linkage analysis (Zimprich et al., 2004). Intragenic the pathology material for reevaluation, and Dr. Y. Tsuboi assisted
markers for haplotype analysis for family 469 and family D were in neuropathologic studies.
established by searching the whole gene for repeat polymorphisms
using a “tandem repeat finding program” (http://c3.biomath.mssm.
Received: October 22, 2004
edu/trf.html). Polymorphic repeats were found in intron 5 (caa), in-
Revised: October 28, 2004
tron 20 (atct), and intron 29 (ac). Primer sequences for intragenic
Accepted: November 1, 2004
markers are available from the authors on request.
Published: November 17, 2004
Linkage Analysis
Two point LOD scores were calculated using the MLINK program
References(V 5.10) in its FASTLINK implementation (V4.1P). Phenocopy rate
was set at 0.01 and penetrance for the heterozygous state and
Arvanitakis, Z., and Wszolek, Z.K. (2001). Recent advances in thehomozygous mutation carriers at 0.90. The allele frequency of the
understanding of tau protein and movement disorders. Curr. Opin.disease-causing allele was set at 0.001, as was the frequency of
Neurol. 14, 491–497.the mutation used as the marker.
Screening of Mutations and Polymorphisms Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J.,
Mutation screening was performed using an ABI 7900 Allelic Detec- Kreiger, E., Dekker, M.C., Squitieri, F., Ibanez, P., Joose, M., et
tion system. PCR was performed by using Taqman Universal PCR al. (2003). Mutations in the DJ-1 gene associated with autosomal
Master Mix and Assays-on-Demand MGB primer and dye-labeled recessive early-onset Parkinsonism. Science 299, 256–259.
probe sets (Applied Biosystems). For each mutation and polymor- Bosgraaf, L., and Van Haastert, P.J. (2003). Roc, a Ras/GTPase
phism, at least 1200 control chromosomes from a mixed European domain in complex proteins. Biochim. Biophys. Acta 1643, 5–10.
descent were screened. In addition, we screened 300 patients with
Chartier-Harlin, M.C., Kachergus, J., Roumie, R.C., Mouroux, V.,sporadic PD. Genotyping was performed on a MALDI-TOF mass-
Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan,spectrometer (Sequenom MassArray system) using the homoge-
M., et al. (2004). Alpha-synuclein locus duplication as a cause ofneous mass-extension (hME) process for producing primer exten-
familial Parkinson’s disease. Lancet 364, 1167–1169.sion products (Tang et al., 1999).
Amplification of LRRK2 Dickson, D.W. (1999). Neuropathologic differentiation of progressive
The complete coding sequence of LRRK2 was amplified from human supranuclear palsy and corticobasal degeneration. J. Neurol. 246
brain cDNA by using Marathon-Ready cDNA (BD Biosciences Clon- (Suppl 2), 6–15.
tech). Primers were set to amplify three overlapping fragments from Duda, J.E., Giasson, B.I., Mabon, M.E., Miller, D.C., Golbe, L.I., Lee,
exons 1–21 (P1f, P1r), from exons 20–35 (p2f, p2r), and from exons V.M., and Trojanowski, J.Q. (2002). Concurrence of alpha-synuclein
34–51 (p3f, p3r) (Figure 3). Sequence information was derived from and tau brain pathology in the Contursi kindred. Acta Neuropathol.
published mRNA of DKFZp434H211. PCR products were run on (Berl.) 104, 7–11.
agarose gel to check length and integrity. All oligonucleotides are
Farrer, M., Gwinn-Hardy, K., Hutton, M., and Hardy, J. (1999). Theavailable upon request.
genetics of disorders with synuclein pathology and Parkinsonism.Northern Blot Analysis
Hum. Mol. Genet. 8, 81–85.Northern blot analysis was performed according to the manufactur-
Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., ander’s protocols (BD Biosciences). For hybridization, we used a LRRK2
Obata, F. (2002). A new locus for Parkinson’s disease (PARK8) mapscDNA fragment (bp 6577–7655) corresponding to exon 45-3UTR.
LightCycler Experiments to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296–301.
mRNAs from different human tissues were purchased from BD Bio- Gasser, T., Mu¨ller-Myhsok, B., Wszolek, Z.K., Oehlmann, R., Calne,
sciences (Clontech BD Sciences, Palo Alto, CA) and were reverse D.B., Bonifati, V., Bereznai, B., Fabrizio, E., Vieregge, P., and Horst-
transcribed with the Transciptor First Strand cDNA Synthesis Kit mann, R.D. (1998). A susceptibility locus for Parkinson’s disease
(Roche Applied Sciences, Mannheim, Germany) according to the maps to chromosome 2p13. Nat. Genet. 18, 262–265.
manufacturer’s protocol. For real-time amplification of LRRK2, three
Ghetti, B., Hutton, M., and Wszolek, Z.K. (2003). Frontotemporalspecific PCR products spanning exons 1–3, exons 12–13, and exons
dementia and parkinsonism linked to chromosome 17 associated32–34 were quantified using the LightCycler Instrument (Roche Ap-
with tau gene mutations (FTDP-17). In Neurodegeneration: The Mo-plied Sciences). Fluorescence-labeled hybridization probes provid-
lecular Pathology of Dementia and Movement Disorders, D.W. Dick-ing maximum specificity were used for product detection. Calcula-
son, ed. (Basel, Switzerland: ISN Neuropath Press), pp. 86–102.tion of sample concentrations were performed using the fit-point
Giasson, B.I., Forman, M.S., Higuchi, M., Golbe, L.I., Graves, C.L.,algorithm. The porphobilinogen deaminase (h-PBGD) gene, a low-
copy housekeeping gene, was used as an external standard and Kotzbauer, P.T., Trojanowski, J.Q., and Lee, V.M. (2003). Initiation
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and synergistic fibrillization of tau and alpha-synuclein. Science rer, M.J., et al. (2004). Autosomal dominant parkinsonism associated
with variable synuclein and tau pathology. Neurology 62, 1619–1622.300, 636–640.
Zimprich, A., Muller-Myhsok, B., Farrer, M., Leitner, P., Sharma, M.,Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R.M. (2001). Formation
Hulihan, M., Lockhart, P., Strongosky, A., Kachergus, J., Calne, D.B.,of neurofibrillary tangles in P301l tau transgenic mice induced by
et al. (2004). The PARK8 locus in autosomal dominant Parkinsonism:Abeta 42 fibrils. Science 293, 1491–1495.
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